Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory S Basarab

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Antimicrobial Agents and Chemotherapy|March 10, 2022
Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to FluoroquinolonesGregory S Basarab, Sandeep Ghorpade, Liezl Gibhard, et al.
Journal of Medicinal Chemistry|June 25, 2014
Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099)Gregory S Basarab, Pamela J Hill, C Edwin Garner, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 5, 2014
Negamycin induces translational stalling and miscoding by binding to the small subunit head domain of the Escherichia coli ribosomeNelson B Olivier, Roger B Altman, Jonas Noeske, et al.
Journal of Medicinal Chemistry|May 12, 2025
Cell-Based Progression of Spiroindoline Phenotypic Hits Leads to the Identification of Compounds with Diverging Parasitological Profiles against the Human Malaria Parasite <i>Plasmodium falciparum</i>Jean Dam, Grant A Boyle, André Horatscheck, et al.
Journal of Medicinal Chemistry|October 7, 2025
Optimization of 2,8-Diaryl-1,5-naphthyridines as <i>Plasmodium falciparum</i> Phosphatidylinositol 4-Kinase Inhibitors with Improved ADME Profiles and In Vivo EfficacyGodwin A Dziwornu, Donald Seanego, Stephen Fienberg, et al.
Scientific Reports|July 15, 2015
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Journal of Medicinal Chemistry|February 11, 2026
Identification of Compound <b>15</b> (MMV1581361) as a <i>Pf</i>ATP4 Inhibitor with Transmission-Blocking Activity and <i>In Vivo</i> Efficacy in a SCID Mouse Model of MalariaHenry A Onyame, Stephen Brand, Delphin Baud, et al.
Journal of Medicinal Chemistry|October 26, 2020
Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and <i>In Vivo</i> Efficacy in the <i>Plasmodium falciparum</i> NSG Mouse ModelAndré Horatscheck, Ana Andrijevic, Aloysius T Nchinda, et al.
Journal of Medicinal Chemistry|August 20, 2021
1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in <i>Mycobacterium tuberculosis</i>Lutete Peguy Khonde, Rudolf Müller, Grant A Boyle, et al.
Journal of Medicinal Chemistry|January 4, 2021
Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action StudiesCandice Soares de Melo, Vinayak Singh, Alissa Myrick, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Antimicrobial Agents and Chemotherapy|March 10, 2022
Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to FluoroquinolonesGregory S Basarab, Sandeep Ghorpade, Liezl Gibhard, et al.
Journal of Medicinal Chemistry|June 25, 2014
Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099)Gregory S Basarab, Pamela J Hill, C Edwin Garner, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 5, 2014
Negamycin induces translational stalling and miscoding by binding to the small subunit head domain of the Escherichia coli ribosomeNelson B Olivier, Roger B Altman, Jonas Noeske, et al.
Journal of Medicinal Chemistry|May 12, 2025
Cell-Based Progression of Spiroindoline Phenotypic Hits Leads to the Identification of Compounds with Diverging Parasitological Profiles against the Human Malaria Parasite <i>Plasmodium falciparum</i>Jean Dam, Grant A Boyle, André Horatscheck, et al.
Journal of Medicinal Chemistry|October 7, 2025
Optimization of 2,8-Diaryl-1,5-naphthyridines as <i>Plasmodium falciparum</i> Phosphatidylinositol 4-Kinase Inhibitors with Improved ADME Profiles and In Vivo EfficacyGodwin A Dziwornu, Donald Seanego, Stephen Fienberg, et al.
Scientific Reports|July 15, 2015
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Journal of Medicinal Chemistry|February 11, 2026
Identification of Compound <b>15</b> (MMV1581361) as a <i>Pf</i>ATP4 Inhibitor with Transmission-Blocking Activity and <i>In Vivo</i> Efficacy in a SCID Mouse Model of MalariaHenry A Onyame, Stephen Brand, Delphin Baud, et al.
Journal of Medicinal Chemistry|October 26, 2020
Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and <i>In Vivo</i> Efficacy in the <i>Plasmodium falciparum</i> NSG Mouse ModelAndré Horatscheck, Ana Andrijevic, Aloysius T Nchinda, et al.
Journal of Medicinal Chemistry|August 20, 2021
1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in <i>Mycobacterium tuberculosis</i>Lutete Peguy Khonde, Rudolf Müller, Grant A Boyle, et al.
Journal of Medicinal Chemistry|January 4, 2021
Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action StudiesCandice Soares de Melo, Vinayak Singh, Alissa Myrick, et al.
Pageof 5